https://www.biopharmawatch.com/news/MRNA/moderna-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-06T00:00:00.000Z Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026 https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-third-quarter-results-2026 BiopharmaWatch en 2026-10-28T00:00:00.000Z ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026 https://www.biopharmawatch.com/news/PFE/pfizer-25-valent-pneumococcal-vaccine-phase-2-results BiopharmaWatch en 2026-10-24T15:18:00.000Z Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026 https://www.biopharmawatch.com/news/AMGN/imdelltra-imfinzi-small-cell-lung-cancer-results BiopharmaWatch en 2026-10-24T14:30:00.000Z IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER https://www.biopharmawatch.com/news/JNJ/apalutamide-reduces-recurrence-risk-prostate-cancer BiopharmaWatch en 2026-10-24T13:01:00.000Z Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-erleada-apalutamide-treatment-surgery-reduces-risk-recurrence BiopharmaWatch en 2026-10-24T12:54:00.000Z Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer https://www.biopharmawatch.com/news/PBLS/parabilis-medicines-zolucatetide-phase-1-2-data BiopharmaWatch en 2026-10-24T12:45:00.000Z Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors https://www.biopharmawatch.com/news/GMAB/incyte-genmab-clinical-trial-collaboration BiopharmaWatch en 2026-10-24T11:00:00.000Z Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer https://www.biopharmawatch.com/news/GMAB/genmab-incyte-clinical-trial-metastatic-colorectal-cancer BiopharmaWatch en 2026-10-24T11:00:00.000Z Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer https://www.biopharmawatch.com/news/NBTX/nanobiotix-phase-1-study-nbtxr3-melanoma-results BiopharmaWatch en 2026-10-24T11:00:00.000Z NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma https://www.biopharmawatch.com/news/ONC/beone-presents-data-esmo-2026 BiopharmaWatch en 2026-10-24T08:15:00.000Z BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026 https://www.biopharmawatch.com/news/CELC/celcuity-updated-results-viktoria-1-study-esmo-2026 BiopharmaWatch en 2026-10-24T08:15:00.000Z Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026 https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-companion-002-results-tovecimig BiopharmaWatch en 2026-10-24T08:15:00.000Z Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026 https://www.biopharmawatch.com/news/LLY/lilly-sofetabart-mipitecan-esmo-2026 BiopharmaWatch en 2026-10-24T06:30:00.000Z Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026 https://www.biopharmawatch.com/news/ZYME/zymeworks-presents-new-phase-1-data-folate-receptor-alpha-targeting BiopharmaWatch en 2026-10-24T06:30:00.000Z Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026 https://www.biopharmawatch.com/news/IMTX/immatics-clinical-activity-ima402-ima203cd8-esmo-2026 BiopharmaWatch en 2026-10-24T06:30:00.000Z Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting https://www.biopharmawatch.com/news/RXST/rxsight-reports-inducement-grants-permitted-nasdaq-listing-rules BiopharmaWatch en 2026-10-24T00:00:00.000Z RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules https://www.biopharmawatch.com/news/TVTX/travere-new-biomarker-data-asn-kidney-week BiopharmaWatch en 2026-10-23T23:20:00.000Z Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-inducement-grants BiopharmaWatch en 2026-10-23T21:00:00.000Z AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-lunit-ai-scope-io-agreement BiopharmaWatch en 2026-10-23T20:37:00.000Z Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-inducement-grants-october-2026 BiopharmaWatch en 2026-10-23T20:15:00.000Z Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SRTA/strata-critical-medical-q3-2026-earnings-call BiopharmaWatch en 2026-10-23T20:05:00.000Z Strata Critical Medical Schedules Third Quarter 2026 Earnings Conference Call https://www.biopharmawatch.com/news/WGS/genedx-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-23T20:05:00.000Z GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026 https://www.biopharmawatch.com/news/CPIX/cumberland-ifetroban-assist-ssc-trial-results BiopharmaWatch en 2026-10-23T20:05:00.000Z Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results https://www.biopharmawatch.com/news/ARDX/ardelyx-xphozah-serum-phosphate-reductions-asn-2026 BiopharmaWatch en 2026-10-23T20:01:00.000Z Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders https://www.biopharmawatch.com/news/CLYM/climb-bio-mabworks-clym116-mil116-asn-kidney-week-2026 BiopharmaWatch en 2026-10-23T20:01:00.000Z Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/ENSG/ensign-group-q3-2026-earnings-call BiopharmaWatch en 2026-10-23T20:01:00.000Z The Ensign Group Schedules Third Quarter 2026 Earnings Call for Wednesday, October 28, 2026 https://www.biopharmawatch.com/news/OFIX/orthofix-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-23T20:00:00.000Z Orthofix to Report Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AVBP/arrivent-phase-1-data-esmo-2026 BiopharmaWatch en 2026-10-23T20:00:00.000Z ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026 https://www.biopharmawatch.com/news/ABBV/fda-approves-skyrizi-subcutaneous-induction-crohns-disease BiopharmaWatch en 2026-10-23T19:33:00.000Z U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease https://www.biopharmawatch.com/news/MDLN/medline-fourth-annual-medtrans-rodeo BiopharmaWatch en 2026-10-23T19:14:00.000Z Medline hosts fourth annual MedTrans Rodeo in Mundelein, Ill. https://www.biopharmawatch.com/news/HTFL/elucid-statement-heartflow-lawsuit BiopharmaWatch en 2026-10-23T18:15:00.000Z Elucid Statement on Heartflow Lawsuit: Reaffirms Mission, Confidence in Its Technology, and Commitment to Patients and Physicians https://www.biopharmawatch.com/news/VRTX/phase-3-rainier-results-supporting-best-class-potential-povetacicept-iga BiopharmaWatch en 2026-10-23T17:42:00.000Z Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026 https://www.biopharmawatch.com/news/VRTX/vertex-povetacicept-iga-nephropathy-results BiopharmaWatch en 2026-10-23T17:42:00.000Z Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026 https://www.biopharmawatch.com/news/IONS/roche-phase-3-data-sefaxersen-iga-nephropathy BiopharmaWatch en 2026-10-23T17:37:00.000Z Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN) https://www.biopharmawatch.com/news/NTHI/neonc-breaks-through-key-levels-brain-cancer-stock BiopharmaWatch en 2026-10-23T17:01:00.000Z NeOnc Breaks Through Key Levels, as Brain-Cancer Stock’s Catalysts Continue https://www.biopharmawatch.com/news/GMAB/genmab-rinatabart-sesutecan-ovarian-cancer-trial-results BiopharmaWatch en 2026-10-23T15:55:00.000Z Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer https://www.biopharmawatch.com/news/NVS/novartis-remibrutinib-phase-iii-results-ms BiopharmaWatch en 2026-10-23T15:45:00.000Z Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-phase-1-azer-cel-progressive-ms BiopharmaWatch en 2026-10-23T14:55:00.000Z TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026 https://www.biopharmawatch.com/news/CATX/perspectives-212pb-bamzireotide-navoxetan-phase-1-2a-trial BiopharmaWatch en 2026-10-23T14:49:00.000Z Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-phase-1-breakfree-2-study-results BiopharmaWatch en 2026-10-23T14:30:00.000Z Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026 https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-miv-cel-ms-toronto-2026 BiopharmaWatch en 2026-10-23T14:30:00.000Z Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026 https://www.biopharmawatch.com/news/JAZZ/ziihera-combinations-survival-her2-advanced-gea BiopharmaWatch en 2026-10-23T14:15:00.000Z Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026 https://www.biopharmawatch.com/news/ONC/beone-medicines-tevimabra-ziihira-gastroesophageal-cancer BiopharmaWatch en 2026-10-23T14:15:00.000Z BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-denali-study-esmo-2026 BiopharmaWatch en 2026-10-23T14:15:00.000Z Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026 https://www.biopharmawatch.com/news/IOVA/iovance-lifileucel-pembrolizumab-esmo-2026 BiopharmaWatch en 2026-10-23T14:15:00.000Z Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma https://www.biopharmawatch.com/news/XBIT/xbiotech-announces-co-ceo-appointments BiopharmaWatch en 2026-10-23T13:17:00.000Z XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers https://www.biopharmawatch.com/news/FTH/faeth-updated-preclinical-data-esmo-2026 BiopharmaWatch en 2026-10-23T13:15:00.000Z Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib https://www.biopharmawatch.com/news/ABT/abbott-esmo-data-oncodetect-test-colorectal-cancer BiopharmaWatch en 2026-10-23T13:15:00.000Z Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer https://www.biopharmawatch.com/news/CELC/celcuity-phase-1b-2-gedatolisib-darolutamide-esmo-2026 BiopharmaWatch en 2026-10-23T13:15:00.000Z Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026 https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-esmo-congress-data BiopharmaWatch en 2026-10-23T13:15:00.000Z Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress https://www.biopharmawatch.com/news/KTTA/pasithea-positive-pas-004-clinical-data-esmo-2026 BiopharmaWatch en 2026-10-23T13:15:00.000Z Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026 https://www.biopharmawatch.com/news/MGNX/macrogenics-positive-phase-1-results-mgc026 BiopharmaWatch en 2026-10-23T13:15:00.000Z MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-acquires-prana-therapies BiopharmaWatch en 2026-10-23T13:08:00.000Z Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-ifetroban-dmd-webcast BiopharmaWatch en 2026-10-23T13:05:00.000Z CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL https://www.biopharmawatch.com/news/BMY/pathos-ai-bms-tempus-ai-collaboration-alzheimers BiopharmaWatch en 2026-10-23T13:00:00.000Z Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions https://www.biopharmawatch.com/news/BMY/tempus-expands-collaboration-bristol-myers-squibb BiopharmaWatch en 2026-10-23T13:00:00.000Z Tempus Expands Strategic Collaboration with Bristol Myers Squibb https://www.biopharmawatch.com/news/LIVN/livanova-core-vns-results-drug-resistant-epilepsy BiopharmaWatch en 2026-10-23T13:00:00.000Z Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy https://www.biopharmawatch.com/news/BMY/pathos-ai-secures-237-million-series-e-financing BiopharmaWatch en 2026-10-23T13:00:00.000Z Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline https://www.biopharmawatch.com/news/CVS/cvs-pharmacy-fall-collectibles-nostalgic-favorites BiopharmaWatch en 2026-10-23T13:00:00.000Z CVS Pharmacy expands fall assortment of collectibles, nostalgic favorites and seasonal exclusives https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-amplify-7p-results-esmo-2026 BiopharmaWatch en 2026-10-23T13:00:00.000Z Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-sonata-hcm-update BiopharmaWatch en 2026-10-23T12:30:00.000Z Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy https://www.biopharmawatch.com/news/IRMD/iradimed-third-quarter-2026-financial-results-call BiopharmaWatch en 2026-10-23T12:30:00.000Z IRADIMED CORPORATION to Hold Third Quarter 2026 Financial Results Conference Call on October 30, 2026 https://www.biopharmawatch.com/news/ONCO/onconetix-additional-financing-realbotix-acquisition BiopharmaWatch en 2026-10-23T12:30:00.000Z Onconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending Acquisition https://www.biopharmawatch.com/news/MBOT/microbot-medical-sir-edge-2026-conference BiopharmaWatch en 2026-10-23T12:30:00.000Z Microbot Medical® Attending Key Medical Conference to Engage with Decision-makers as it Continues to Expand Presence Across the U.S. https://www.biopharmawatch.com/news/WAT/waters-labcorp-hpv-testing-expansion-2026 BiopharmaWatch en 2026-10-23T12:00:00.000Z Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026 https://www.biopharmawatch.com/news/LH/labcorp-waters-hpv-testing-expansion-2026 BiopharmaWatch en 2026-10-23T12:00:00.000Z Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026 https://www.biopharmawatch.com/news/LH/labcorp-acquires-millennium-health BiopharmaWatch en 2026-10-23T12:00:00.000Z Labcorp Announces Definitive Agreement to Acquire Millennium Health https://www.biopharmawatch.com/news/IMMP/immutep-quality-of-life-data-esmo-2026 BiopharmaWatch en 2026-10-23T12:00:00.000Z Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026 https://www.biopharmawatch.com/news/HUMA/humacyte-atev-phase-3-trial-results BiopharmaWatch en 2026-10-23T12:00:00.000Z Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-invincible-4-study-esmo-2026 BiopharmaWatch en 2026-10-23T12:00:00.000Z Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting https://www.biopharmawatch.com/news/ATNM/actinium-phase-1-study-atnm-400-esmo-2026 BiopharmaWatch en 2026-10-23T12:00:00.000Z Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026 https://www.biopharmawatch.com/news/NVS/kisqali-natalee-trial-results-breast-cancer BiopharmaWatch en 2026-10-23T11:30:00.000Z Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence https://www.biopharmawatch.com/news/BMY/iza-bren-reduces-risk-in-advanced-breast-cancer BiopharmaWatch en 2026-10-23T11:30:00.000Z Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study https://www.biopharmawatch.com/news/BMY/iza-bren-phase-3-results-breast-cancer BiopharmaWatch en 2026-10-23T11:30:00.000Z Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study https://www.biopharmawatch.com/news/TAK/takeda-tak-921-phase-3-advanced-gastric-cancer-study BiopharmaWatch en 2026-10-23T11:30:00.000Z Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study https://www.biopharmawatch.com/news/BCTX/briacell-esmo-2026-circulating-immune-biomarker BiopharmaWatch en 2026-10-23T11:30:00.000Z BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer https://www.biopharmawatch.com/news/RVMD/rasonque-overall-survival-data-esmo-2026 BiopharmaWatch en 2026-10-23T11:30:00.000Z Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026 https://www.biopharmawatch.com/news/JNJ/ec-approves-johnson-johnson-tecvayli-multiple-myeloma BiopharmaWatch en 2026-10-23T11:09:00.000Z European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse https://www.biopharmawatch.com/news/TMCI/treace-report-third-quarter-2026-results BiopharmaWatch en 2026-10-23T11:05:00.000Z Treace to Report Third Quarter 2026 Financial Results on November 6, 2026 https://www.biopharmawatch.com/news/MRNA/moderna-top-employer-science-2026 BiopharmaWatch en 2026-10-23T11:00:00.000Z Moderna Named a Top Employer by Science for Twelfth Consecutive Year https://www.biopharmawatch.com/news/BLRX/biolinerx-hemispherian-present-preclinical-data-demonstrating-synergy-glix1-parp BiopharmaWatch en 2026-10-23T11:00:00.000Z BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026 https://www.biopharmawatch.com/news/BKD/brookdale-q3-2026-earnings-release-conference-call BiopharmaWatch en 2026-10-23T11:00:00.000Z Brookdale Announces Third Quarter 2026 Earnings Release and Conference Call https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-hero-trial-data BiopharmaWatch en 2026-10-23T11:00:00.000Z Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-q3-2026-financial-results-discussion BiopharmaWatch en 2026-10-23T10:55:00.000Z ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET https://www.biopharmawatch.com/news/MEDS/datameds-ai-health-lives-here-community-respiratory-program BiopharmaWatch en 2026-10-23T10:45:00.000Z DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network https://www.biopharmawatch.com/news/ZLAB/zai-lab-zocilurtatug-pelitecan-es-sclc-trial-results BiopharmaWatch en 2026-10-23T10:33:00.000Z Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer https://www.biopharmawatch.com/news/TNGX/tango-phase-1-2-study-vopimetostat-daraxonrasib BiopharmaWatch en 2026-10-23T10:30:00.000Z Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy https://www.biopharmawatch.com/news/IDYA/ide849-updated-phase-1-results-esmo-2026 BiopharmaWatch en 2026-10-23T10:00:00.000Z IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas https://www.biopharmawatch.com/news/ZYME/zymeworks-roche-license-agreement-zw209 BiopharmaWatch en 2026-10-23T10:00:00.000Z Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3 https://www.biopharmawatch.com/news/PHAT/phathom-update-litigation-bdr-fda BiopharmaWatch en 2026-10-23T08:00:00.000Z Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA https://www.biopharmawatch.com/news/ALNY/alny-positive-phase-1b-data-brezosiran-huntingtons-disease BiopharmaWatch en 2026-10-23T07:45:00.000Z Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-rinzimetostat-esmo-congress-2026 BiopharmaWatch en 2026-10-23T07:15:00.000Z ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026 https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-enozertinib-phase-3-trial BiopharmaWatch en 2026-10-23T07:15:00.000Z ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial https://www.biopharmawatch.com/news/EVAX/evaxion-evx-01-three-year-trial-results BiopharmaWatch en 2026-10-23T06:00:00.000Z Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-private-placement-250-million BiopharmaWatch en 2026-10-23T00:52:00.000Z Zai Lab Announces $250 Million Private Placement https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-voluntarily-delist-nasdaq BiopharmaWatch en 2026-10-22T23:00:00.000Z Lunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister https://www.biopharmawatch.com/news/MLYS/mineralys-lorundrostat-asn-kidney-week-2026 BiopharmaWatch en 2026-10-22T22:40:00.000Z Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-presentation-emerging-growth-conference BiopharmaWatch en 2026-10-22T22:27:00.000Z Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference https://www.biopharmawatch.com/news/ENLV/enlivex-reverse-share-split-effective-october-2026 BiopharmaWatch en 2026-10-22T21:16:00.000Z Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026 https://www.biopharmawatch.com/news/HYFT/mindwalk-holdings-leadership-update BiopharmaWatch en 2026-10-22T21:00:00.000Z MindWalk Holdings Corp. Announces Leadership Update https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-third-quarter-2026-results BiopharmaWatch en 2026-10-22T20:43:00.000Z Nu Skin Enterprises to Announce Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/FOCL/focaltherics-third-quarter-2026-results-announcement BiopharmaWatch en 2026-10-22T20:30:27.000Z FocalTherics™ to Announce Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/LH/charles-river-labcorp-fda-collaboration-abuse-potential BiopharmaWatch en 2026-10-22T20:30:00.000Z Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment https://www.biopharmawatch.com/news/AGEN/agenus-third-quarter-2026-financial-report BiopharmaWatch en 2026-10-22T20:30:00.000Z Agenus to Provide Third Quarter 2026 Financial Report and Development Update https://www.biopharmawatch.com/news/LH/labcorp-fda-charles-river-research-collaboration-drug-abuse-potential BiopharmaWatch en 2026-10-22T20:30:00.000Z Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential https://www.biopharmawatch.com/news/EHC/encompass-health-westover-hills-open-texas BiopharmaWatch en 2026-10-22T20:30:00.000Z Encompass Health Rehabilitation Hospital of Westover Hills now open in Texas https://www.biopharmawatch.com/news/CVRX/cvrx-third-quarter-2026-results-conference-call BiopharmaWatch en 2026-10-22T20:30:00.000Z CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026 https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-medicare-reimbursement-esoguard-financing BiopharmaWatch en 2026-10-22T20:20:00.000Z Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing https://www.biopharmawatch.com/news/PROF/montel-williams-joins-lets-huddle-webinar BiopharmaWatch en 2026-10-22T20:15:00.000Z Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let’s Huddle’ Webinar https://www.biopharmawatch.com/news/CDRE/cadre-holdings-q3-2026-earnings-call BiopharmaWatch en 2026-10-22T20:15:00.000Z Cadre Holdings Announces Third Quarter 2026 Earnings and Conference Call Information https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-conference-call-q3-2026 BiopharmaWatch en 2026-10-22T20:11:00.000Z Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AORT/artivion-q3-2026-financial-results-teleconference BiopharmaWatch en 2026-10-22T20:10:00.000Z Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/VOR/telitacicept-preserves-kidney-function-phase-3-trial BiopharmaWatch en 2026-10-22T20:05:17.000Z Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy https://www.biopharmawatch.com/news/ABCL/abcellera-investor-conferences-november-2026 BiopharmaWatch en 2026-10-22T20:05:00.000Z AbCellera to Present at Upcoming Investor Conferences in November 2026 https://www.biopharmawatch.com/news/ABCL/abcellera-present-investor-conferences-november-2026 BiopharmaWatch en 2026-10-22T20:05:00.000Z AbCellera to Present at Upcoming Investor Conferences in November 2026 https://www.biopharmawatch.com/news/ACH/accendra-health-q3-2026-earnings-release BiopharmaWatch en 2026-10-22T20:05:00.000Z Accendra Health Announces Third Quarter 2026 Earnings Release Date and Conference Call https://www.biopharmawatch.com/news/PIII/p3-health-partners-q3-2026-earnings-release BiopharmaWatch en 2026-10-22T20:05:00.000Z P3 Health Partners Schedules Third Quarter 2026 Earnings Release and Conference Call https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-q3-2026-results-conference-call BiopharmaWatch en 2026-10-22T20:05:00.000Z Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026 https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261022 BiopharmaWatch en 2026-10-22T20:05:00.000Z Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/GILD/gilead-acquires-hcxt-2001-inflammation-pipeline BiopharmaWatch en 2026-10-22T20:05:00.000Z Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD https://www.biopharmawatch.com/news/HCAT/health-catalyst-q3-2026-results-conference-call BiopharmaWatch en 2026-10-22T20:05:00.000Z Health Catalyst to Announce Third Quarter 2026 Operating Results and Host Conference Call on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-fda-lifts-hold-ard-101 BiopharmaWatch en 2026-10-22T20:05:00.000Z Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data https://www.biopharmawatch.com/news/FTRE/fortrea-omico-collaboration-precision-oncology BiopharmaWatch en 2026-10-22T20:05:00.000Z Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development https://www.biopharmawatch.com/news/TMDX/transmedics-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-22T20:05:00.000Z TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-hyperphagia-prader-willi-syndrome BiopharmaWatch en 2026-10-22T20:05:00.000Z Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261022 BiopharmaWatch en 2026-10-22T20:05:00.000Z Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ELUT/elutia-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-22T20:05:00.000Z Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-q3-2026-results-call BiopharmaWatch en 2026-10-22T20:01:00.000Z Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026 https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-q3-2026-results-business-update BiopharmaWatch en 2026-10-22T20:01:00.000Z Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026 https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-third-quarter-2026-results BiopharmaWatch en 2026-10-22T20:01:00.000Z Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026 https://www.biopharmawatch.com/news/ANIK/anika-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-22T20:01:00.000Z Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026 https://www.biopharmawatch.com/news/LGND/ligand-investor-day-december-2026 BiopharmaWatch en 2026-10-22T20:01:00.000Z Ligand to Host Investor Day on December 8, 2026 https://www.biopharmawatch.com/news/ACET/adicet-bio-investor-conferences-november-2026 BiopharmaWatch en 2026-10-22T20:00:00.000Z Adicet Bio to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/COSM/cosmos-health-expands-ecommerce-oceania BiopharmaWatch en 2026-10-22T19:55:00.000Z Cosmos Health Expands E-Commerce and Subscription Business to Australia, New Zealand and the Broader Oceania Region, With Sales Already Underway